At RSNA 2023, Nvidia launched new set of cloud-based APIs designed to speed up the creation and deployment of specialized AI models in the medical imaging field. The new offering is a cloud-native extension to Nvidia's Monai framework, which is its open-source framework for medical imaging AI.
Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.
Nvidia and Medtronic recently announced a collaboration focused on embedding AI into medical devices. The two companies plan to create marketplace for AI applications that will allow developers and clinicians to develop their own algorithms to use on Medtronic’s medical devices.
A collaboration between Nvidia and startup Evozyne was able to produce novel versions of a human protein never before seen in nature but with enhanced function and the same safety as native protein. The research lays the groundwork for potential new therapies for a rare inherited disorder.
Nvidia unveiled new tools designed to make it easier for hospitals to integrate AI models related to medical imaging into their clinical workflows. The tools have been adopted by major cloud infrastructure providers, as well as healthcare providers and AI software companies. Some of these include Cincinnati Children’s Hospital, University of California San Francisco, England’s National Health Service and Qure.ai.
Google Cloud unveiled a new product suite to make medical imaging data more interoperable and useful via artificial intelligence. Hackensack Meridian Health has begun using it to detect metastasis in prostate cancer patients earlier, and Hologic is using it to strengthen its diagnostic platform that screens women for cervical cancer.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The metaverse holds promising potential to transform healthcare delivery for the better, according to a keynote talk delivered at MedCity's Invest Digital Health conference. The speaker identified workforce training, patient experience, healthcare facilities and medical manufacturing as the main areas poised for disruption.
Dr. Mona Flores, Global Head of Medical AI at Nvidia, will deliver the keynote talk kicking off the MedCity INVEST Digital Health conference, scheduled for Wednesday, September 28, in Dallas and presented in collaboration with Health Wildcatters. Register today.
The technology company is launching an alliance connecting the AI-driven medical imaging startups in its accelerator program to the GE Healthcare Edison Developer Program and Nuance AI Marketplace for diagnostic imaging.
The chipmaker touted a new framework that would allow hospitals and pharmaceutical companies to collaborate on AI projects without sharing sensitive data. Nvidia said the framework is already gaining traction with hospitals and drug developers.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A new partnership between Nvidia and the American College of Radiology will give a wider range of clinicians the ability to build, share and adapt their own AI models.
Updates to the company's Clara healthcare platform are trying to make it easier for clinicians to train and adapt deep learning algorithms, while also making the implementation process smoother.
During a presentation at Nvidia's GTC 2019 Conference in San Jose, Topol sketched out a vision of a world where this multi-modal data is collected and assessed from "the pre-womb to the tomb" and run through clinically validated algorithms that can reveal personalized insights and aid in more accurate diagnoses.
The company is hoping to boost the adoption of AI in medical imaging with new software development kits and deals with Ohio State University and the NIH.
The company introduced its Clara platform, a combination of a new GPU-based hardware architecture and a software development kit allowing third-party developers to build applications for medical imaging.
